We recently reported a high instability of HER2-low-positive expression from primary breast cancer to relapse8, suggesting that a not negligible proportion of patients originally classified as HER2-0 becomes HER2-low-positive at recurrence thus potentially expanding their therapeutic options. This evidence concerns the gene ERBB2 and breast cancer.